<SEC-DOCUMENT>0001193125-15-132800.txt : 20150416
<SEC-HEADER>0001193125-15-132800.hdr.sgml : 20150416
<ACCEPTANCE-DATETIME>20150416122933
ACCESSION NUMBER:		0001193125-15-132800
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150416
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150416
DATE AS OF CHANGE:		20150416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		15773932

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d908511d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act Of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April 16, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>BRISTOL-MYERS SQUIBB COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>1-1136</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>22-0790350</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>345 Park Avenue </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY, 10154 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Office) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (212)&nbsp;546-4000 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (<I>see</I> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2015, Bristol-Myers Squibb Company (the
&#147;Company&#148;) and Eli Lilly and Company (&#147;Lilly&#148;) issued a joint press release announcing that the companies have agreed to transfer all rights of Erbitux (cetuximab) in North America from the Company to Lilly. The transaction is
expected to result in a non-cash pre-tax charge of approximately $150 million to $200 million during 2015, which will be a specified item.&nbsp;Royalties are expected to be accounted for as other income. The transaction is not expected to have a
significant impact on our non-GAAP earnings. A copy of the press release announcing the transaction is filed as Exhibit 99.1 to this report and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Press release of Bristol-Myers Squibb Company dated April 16, 2015.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3">BRISTOL-MYERS SQUIBB COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: April 16, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sandra Leung</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Sandra Leung</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">General Counsel and Corporate Secretary</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Press release of Bristol-Myers Squibb Company dated April&nbsp;16, 2015.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d908511dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CONFIDENTIAL</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g908511ex99_1pg001a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g908511ex99_1pg001b.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lilly, Bristol-Myers Squibb Restructure Erbitux<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(cetuximab) Collaboration </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in North America </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Full Commercialization Rights Transferred to Lilly </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Indianapolis and New York, April&nbsp;16, 2015) &#150; <U>Eli Lilly and Company</U> (NYSE: LLY) and <U>Bristol-Myers Squibb Company</U>
(NYSE: BMY) today announced that the companies have agreed to transfer rights to <I>Erbitux<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I> (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Bristol-Myers
Squibb to Lilly. Rights include, but are not limited to, full commercialization and manufacturing operational responsibilities. The companies&#146; decision comes after a 14-year successful collaboration, which includes Lilly&#146;s wholly-owned
subsidiary ImClone LLC. Bristol-Myers Squibb and Lilly will work closely to ensure a smooth transition on this important product for patients with certain advanced colorectal and head and neck cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Fully bringing <I>Erbitux</I> into the Lilly Oncology portfolio accelerates Lilly&#146;s commitment and leadership in gastrointestinal
cancers to include an effective treatment for advanced colorectal cancer as well as head and neck cancer,&#148; said Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology. &#147;Our good work on <I>Erbitux</I> began with its
development at ImClone and has continued with Bristol-Myers Squibb. We look forward to carrying on these efforts for people battling select advanced colorectal and head and neck cancers.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Bristol-Myers Squibb is incredibly proud to have built <I>Erbitux</I> into a major brand and an important therapy for so many patients
with certain colorectal and head and neck cancers,&#148; said Murdo Gordon, head of worldwide markets, Bristol-Myers Squibb. &#147;This agreement further aligns our Oncology organization with our prioritized opportunities in immuno-oncology, across
both solid tumors and hematologic malignancies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transition is expected to be completed in the fourth quarter of 2015.
Bristol-Myers Squibb will receive tiered royalties based on net product sales in North America after the completion of the transition through September 2018. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About </U></B><B><I><U>Erbitux</U></I></B><B><U> </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Erbitux</I> is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Head and Neck Cancer </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Erbitux</I>, in combination with radiation therapy, is indicated for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Erbitux</I> is indicated in combination with platinum-based therapy with 5-FU for the first-line treatment of patients with recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Erbitux</I>, as a single agent, is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Colorectal Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Erbitux</I> is indicated for the
treatment of <I>KRAS</I> (wild-type), epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by FDA-approved tests for this use: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Limitation of Use: <I>Erbitux</I> is not indicated for treatment of <I>Ras-mutant</I> colorectal cancer or when the results of the <I>Ras</I> mutation tests
are unknown. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Infusion Reactions </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Grade 3/4 infusion reactions occurred in approximately 3% of patients receiving ERBITUX&reg; (cetuximab) in clinical trials, with fatal outcome reported in less than 1 in 1000</B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Serious infusion reactions, requiring medical intervention and immediate, permanent discontinuation of ERBITUX, included rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), hypotension, shock, loss
of consciousness, myocardial infarction, and/or cardiac arrest</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Immediately interrupt and permanently discontinue ERBITUX infusion for serious infusion reactions</B> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Approximately 90% of the severe infusion reactions were associated with the first infusion of ERBITUX despite premedication with antihistamines</B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Caution must be exercised with every ERBITUX infusion, as there were patients who experienced their first severe infusion reaction during later infusions</B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Monitor patients for 1 hour following ERBITUX infusions in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (eg, epinephrine, corticosteroids, intravenous antihistamines,
bronchodilators, and oxygen). Longer observation periods may be required in patients who require treatment for infusion reactions</B> </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cardiopulmonary Arrest </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Cardiopulmonary arrest and/or sudden death occurred in 4 (2%) of 208 patients with squamous cell carcinoma of the head and neck treated with radiation therapy and ERBITUX, as compared to none of 212 patients treated
with radiation therapy alone. In 3 patients with prior history of coronary artery disease, death occurred 27, 32, and 43 days after the last dose of ERBITUX. One patient with no prior history of coronary artery disease died one day after the last
dose of ERBITUX. Fatal cardiac disorders and/or sudden death occurred in 7 (3%)&nbsp;of the 219 patients with squamous cell carcinoma of the head and neck treated with platinum-based therapy with 5-fluorouracil (5-FU) and European Union
(EU)-approved cetuximab as compared to 4 (2%)&nbsp;of the 215 patients treated with chemotherapy alone. Five of these 7 patients in the chemotherapy plus cetuximab arm received concomitant cisplatin and 2 patients received concomitant carboplatin.
All 4 patients in the chemotherapy-alone arm received cisplatin</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Carefully consider the use of ERBITUX in combination with radiation therapy or platinum-based therapy with 5-FU in head and neck cancer patients with a history of coronary artery disease, congestive heart failure, or
arrhythmias in light of these risks</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium during and after ERBITUX therapy</B> </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pulmonary Toxicity </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Interstitial lung disease (ILD), which was fatal in one case, occurred in 4 of 1570 (&lt;0.5%) patients receiving ERBITUX in Studies 1, 3, and 6, as well as other studies, in colorectal cancer and head and neck cancer.
Interrupt ERBITUX for acute onset or worsening of pulmonary symptoms. Permanently discontinue ERBITUX for confirmed ILD </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dermatologic
Toxicities </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In clinical studies of ERBITUX, dermatologic toxicities, including acneiform rash, skin drying and fissuring, paronychial inflammation, infectious sequelae (eg, <I>S. aureus</I> sepsis, abscess formation, cellulitis,
blepharitis, conjunctivitis, keratitis/ulcerative keratitis with decreased visual acuity, cheilitis), and hypertrichosis, occurred in patients receiving ERBITUX therapy. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Acneiform rash occurred in 76-88% of 1373 patients receiving ERBITUX in Studies 1, 3, 5, and 6. Severe acneiform rash occurred in 1-17% of patients. Acneiform rash usually developed within the first 2 weeks of therapy
and resolved in a majority of the patients after cessation of treatment, although in nearly half, the event continued beyond 28 days </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Life-threatening and fatal bullous mucocutaneous disease with blisters, erosions, and skin sloughing has also been observed in patients treated with Erbitux. It could not be determined whether these mucocutaneous
adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune-related effects (eg, Stevens Johnson syndrome or toxic epidermal necrolysis) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Monitor patients receiving ERBITUX for dermatologic toxicities and infectious sequelae </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sun exposure may exacerbate these effects </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ERBITUX Plus Radiation Therapy and Cisplatin </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In a controlled study, 940 patients with locally advanced SCCHN were randomized 1:1 to receive either ERBITUX in combination with radiation therapy and cisplatin or radiation therapy and cisplatin alone. The addition of
ERBITUX resulted in an increase in the incidence of Grade 3-4 mucositis, radiation recall syndrome, acneiform rash, cardiac events, and electrolyte disturbances compared to radiation and cisplatin alone </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adverse reactions with fatal outcome were reported in 20 patients (4.4%)&nbsp;in the ERBITUX combination arm and 14 patients (3.0%)&nbsp;in the control arm </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Nine patients in the ERBITUX arm (2.0%)&nbsp;experienced myocardial ischemia compared to 4 patients (0.9%) in the control arm </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The addition of ERBITUX to radiation and cisplatin did not improve progression-free survival (the primary endpoint) </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electrolyte Depletion </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hypomagnesemia occurred in 55% of 365 patients receiving ERBITUX in Study 5 and two other clinical trials in colorectal cancer and head and neck cancer, respectively, and was severe (NCI CTC grades 3 &amp; 4) in 6-17%.
In Study 2 the addition of EU-approved cetuximab to cisplatin and 5-FU resulted in an increased incidence of hypomagnesemia (14% vs 6%) and of grade 3&#150;4 hypomagnesemia (7% vs 2%) compared to cisplatin and 5-FU alone. In contrast, the incidences
of hypomagnesemia were similar for those who received cetuximab, carboplatin, and 5-FU compared to carboplatin and 5-FU (4% vs 4%). No patient experienced grade 3&#150;4 hypomagnesemia in either arm in the carboplatin subgroup. The onset of
hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of ERBITUX therapy </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Monitor patients periodically for hypomagnesemia, hypocalcemia, and hypokalemia, during, and for at least 8 weeks following the completion of, ERBITUX therapy </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Replete electrolytes as necessary </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Increased Tumor Progression, Increased Mortality, or Lack of Benefit in Patients with Ras-Mutant mCRC </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Erbitux is not indicated for the treatment of patients with colorectal cancer that harbor somatic mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either K-Ras or
N-Ras </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on retrospective subset analyses of Ras-mutant and wild-type populations across several randomized clinical trials of anti-EGFR-directed monoclonal antibodies, including Study 4, use of cetuximab in patients with
Ras mutations resulted in no clinical benefit with treatment related toxicity </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Late Radiation Toxicities </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The overall incidence of late radiation toxicities (any grade) was higher with ERBITUX in combination with radiation therapy compared with radiation therapy alone. The following sites were affected: salivary glands (65%
vs 56%), larynx (52% vs 36%), subcutaneous tissue (49% vs 45%), mucous membranes (48% vs 39%), esophagus (44% vs 35%), and skin (42% vs 33%) in the ERBITUX and radiation versus radiation-alone arms, respectively </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The incidence of grade 3 or 4 late radiation toxicities was similar between the radiation therapy alone and the ERBITUX plus radiation therapy arms </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pregnancy and Nursing </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In women of childbearing potential and men, appropriate contraceptive measures must be used during treatment with ERBITUX and for 6 months following the last dose of ERBITUX. ERBITUX may be transmitted from the mother
to the developing fetus, and has the potential to cause fetal harm when administered to pregnant women. ERBITUX should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It is not known whether ERBITUX is secreted in human milk. IgG antibodies, such as ERBITUX, can be excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from ERBITUX, a
decision should be made whether to discontinue nursing or to discontinue ERBITUX, taking into account the importance of ERBITUX to the mother. If nursing is interrupted, based on the mean half-life of cetuximab, nursing should not be resumed earlier
than 60 days following the last dose of ERBITUX </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adverse Reactions </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most <B>serious adverse reactions</B> associated with ERBITUX are infusion reactions, cardiopulmonary arrest, dermatologic toxicity and radiation dermatitis, sepsis, renal failure, interstitial lung disease, and
pulmonary embolus </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most common adverse reactions associated with ERBITUX (incidence <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>25%) across all studies were cutaneous adverse reactions (including rash, pruritus, and nail changes),
headache, diarrhea, and infection </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most frequent adverse reactions seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) (incidence <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50%) were acneiform rash (87% vs 10%), radiation dermatitis (86% vs 90%), weight loss (84% vs 72%), and asthenia (56% vs 49%). The most common grade 3/4 adverse reactions for ERBITUX in combination with
radiation therapy (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10%) versus radiation alone included: radiation dermatitis (23% vs 18%), acneiform rash (17% vs 1%), and weight loss (11% vs 7%) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most frequent adverse reactions seen in patients with carcinomas of the head and neck receiving EU-approved cetuximab in combination with platinum-based therapy with 5-FU (CT) (n=219) versus CT alone (n=215)
(incidence <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>40%) were acneiform rash (70% vs 2%), nausea (54% vs 47%), and infection (44% vs 27%). The most common grade 3/4 adverse reactions for cetuximab in combination with CT (<FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10%) versus CT alone included: infection (11% vs 8%). Since U.S.-licensed ERBITUX provides approximately 22% higher exposure relative to the EU-approved cetuximab, the data provided above may underestimate the
incidence and severity of adverse reactions anticipated with ERBITUX for this indication. However, the tolerability of the recommended dose is supported by safety data from additional studies of ERBITUX </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most frequent adverse reactions seen in patients with <I>KRAS</I> mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer treated with EU-approved cetuximab + FOLFIRI (n=317) versus FOLFIRI alone
(n=350) (incidence <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50%) were acne-like rash (86% vs 13%) and diarrhea (66% vs 60%). The most common grade 3/4 adverse reactions (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10%) included: neutropenia
(31% vs 24%), acne-like rash (18% vs &lt;1%), and diarrhea (16% vs 10%). U.S.-licensed ERBITUX provides approximately 22% higher exposure to cetuximab relative to the EU-approved cetuximab. The data provided above are consistent in incidence and
severity of adverse reactions with those seen for ERBITUX in this indication. The tolerability of the recommended dose is supported by safety data from additional studies of ERBITUX </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most frequent adverse reactions seen in patients with <I>KRAS</I> mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer treated with ERBITUX + best supportive care (BSC) (n=118) versus BSC
alone (n=124) (incidence <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50%) were rash/desquamation (95% vs 21%), fatigue (91% vs 79%), nausea (64% vs 50%), dry skin (57% vs 15%), pain-other (59% vs 37%), and constipation (53% vs 38%). The most
common grade 3/4 adverse reactions (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10%) included: fatigue (31% vs 29%), pain-other (18% vs 10%), rash/desquamation (16% vs 1%), dyspnea (16% vs 13%), other-gastrointestinal (12% vs 5%), and infection
without neutropenia (11% vs 5%) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The most frequent adverse reactions seen in patients with EGFR-expressing metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50%) were acneiform rash (88%), asthenia/malaise (73%), diarrhea (72%), and nausea (55%). The most common grade 3/4 adverse reactions (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10%) included:
diarrhea (22%), leukopenia (17%), asthenia/malaise (16%), and acneiform rash (14%)</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please read the <U>U.S. Full Prescribing Information</U>
including <B>Boxed WARNINGS</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Eli Lilly and Company </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more
than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those
who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at <U>www.lilly.com</U> and
<U>http://newsroom.lilly.com/social-channels</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Bristol-Myers Squibb </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please visit <U>www.bms.com</U> or follow us on Twitter at <U>http://twitter.com/bmsnews</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Erbitux</I> is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bristol-Myers Squibb and Eli Lilly and Company Forward-Looking Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; (as that term is defined in the Private Securities Litigation Reform Act of 1995)
regarding the parties&#146; North American collaboration for ERBITUX. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them,
and could cause actual outcomes and results to differ materially from current expectations. Among other risks, there can be no guarantee that the transition will be completed in the timeframe described in this release. In addition, the amount of
royalties paid to Bristol-Myers Squibb through September 2018 may differ from current expectations. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb&#146;s and
Lilly&#146;s businesses, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb&#146;s and Lilly&#146;s Annual Reports on Form 10-K for the year ended December&nbsp;31, 2014, in their Quarterly
Reports on Form 10-Q and their Current Reports on Form 8-K. Neither Bristol-Myers Squibb nor Lilly undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>#&nbsp;&nbsp;&nbsp;&nbsp;#&nbsp;&nbsp;&nbsp;&nbsp;# </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bristol-Myers Squibb </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ken Dominski, 609-252-5251, <U>ken.dominski@bms.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah
Koenig, 609-252-4145, <U>sarah.koenig@bms.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eli Lilly and Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Crystal Livers-Powers, 317-476-4160, <U>livers_powers_crystal@lilly.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bristol-Myers Squibb </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ranya Dajani, 609-252-5330, <U>ranya.dajani@bms.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eli
Lilly and Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phil Johnson, 317-655-6874, <U>johnson_philip_l@lilly.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g908511ex99_1pg001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g908511ex99_1pg001a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)0#R`P$1``(1`0,1`?_$`+,```$#!0$!````````
M``````@`!@D"!`4'"@,!`0`!!`,!````````````````!`4&!P$"`P@0```'
M``$#`P(#!`8(!P````$"`P0%!@<(`!$2(1,),105%A=!42(C88$R<B08\*'!
M0E(S)1F1X?&B-C<*$0`"`0(%`@4!!04&!`<````!`@,1!``A$@4&,4%182(3
M!Q1Q@3)"%?"14G(6H6(C,S0(L24F%\&B<Z.$I#7_V@`,`P$``A$#$0`_`.^E
M\^;1K5U(/W2#)@Q;KO'KMRHFBV:,VJ9UW+IPLH)2)(-T$Q.<YA`"E`1'TZ%#
M2,(XQZV-*=SX4^WPQSDE2)#)(:(H))[`"IJ?L`SQ#W/<K.4=QV!DUK,I`YCE
MLY:WE?H3-]7HDTO<HQ[!5.6K"\Y8K-&S:%.M$P,Z@HBB=H=K[$RS*J5,4'2A
M;5CXYQNUV;W)0USN@C#R$,U(S5@P"HRZU%.M:U4]:@8I"XYARV]W]8;>1;3:
M))"D?HCJU0I0L\BN$9@:@$::$5I@A!U*\JNQJD?K.YO=>\0$^-&QO)V=K8IF
M.9%.9E9Q>LA26%-47()2S@R1XY7L)43*K`*/4:%A;Z/J'M[1=OZ^[[LQ4_W0
MON:R_P#=I4=Z=<2T[CN#-]+%>WYW8=8/I[<-TZLWLZ`E>C@Y^&-`9QRTY*5W
M7#-]#FJQI.+)VF6@[;/Q<#'QR]&CH6",X>R,%.PK&);7-.&?*"]E7)V:"`0Z
M!5VY/%<ANI)?\<X[-L^NT62UWL1*RHS,5D))ZAB=%1DHK74:'IB([/S'ED&^
MB+<9$N]B,K*SA$4H%`K0HJ:RI-6-*4%1UQ,2DH50I3E.50ARE.0Y#`8AR&`!
M*<IB^ABF`>X"'H/55YU(.1!Q>2MJ`84TD5!'<8J,(AZ!]>W?T_\`0>M2<Z5S
MIC)J,,Z;T6@5EXG'66]4VO2*PE*DPG+/"1+U4Q_[()M7[UNN<3=_0`+Z]+8-
MMW.Z3W;:WFDB'=49A]Y`(PWS[MM5HXBNKJWCEK2CR(I_<2#ATHNDG*22S99)
MP@N0BR+A%0BJ"J)P\B*I*D,8BB9RCW`0$0'I&P=&TN""#0BE"/M![86I*DJA
MXF4H<P0:@CR(Q=?L[]9QTQ\*/<._K]>W^GIT9]^N#[,\5=&#"Z,&/)0_@/?N
M!2@43&$>W8I0[]S&$?0H`'[>M374`._[?;C!(`)/0#]OV.6/-H[;/FR+MFY0
M=M7!`40<M5DG#==,?[*B2R)CI*$']Y1$.NC(T;%'!#CJ"*$?=C6-TD0.A#*1
MU!!!^PC(X\59!FBX*U5>-4W)Q+[;8[E`CA3S$0)X(&."AO(0[!V#U'H$<Q0N
M%8J*Y@$C]_D,SCFUQ#')[;N@D)%`6`.?@.O7(=:XOA^G]76OV=<=\6*4@R5<
MBT3>M%')//W&R;E`[@GM^A_-`AQ5+XB/KW#T'Z];&.4+K96"99D99^?GVQQ2
M>%W]I7C,F>08$Y=<O+OB_P"M<=L+HP871@PNC!A=&##=FK56JT1N>QV2!@"O
M#F3:'FY>.B2N5"]@$C<7Z[?WS`)@[@7N/KUVAM+RXK]-%)+3KI4MI^W2.GVX
M27%]9V=!>3PQ%NFIE75]FHBN+R+FXB:*NI#RT;+IM'!F;M2,?-'Z;9V5)-<S
M1P=HHJ5%R5%<AQ3,(&`ARCV["'?G+%/`P6=60D9!@03YY@98ZPW-O<@M;NCJ
M#F58,*^!H3G3/&6ZUQVPNC!BD3=O3]OU[?OZR!7&*@=<6BKYJBX;M573=)R\
M!46;919(CAT#<@*+_;(',"JX(D-W/X`/B'J/IUC1(5+*&TCJ:5`KT'3_`(G&
MAEC5Q&S*&()`KGEURZG[NF/<5``HF$P`!0$3"(@`%*4.XB(CZ``!Z]_IUJ:G
M(=?VZ99G&Q8+74>G7R'C^U,>;1VV?-TG3-T@\:KE!1!RU627;K)F^AT5D3'2
M5(/[RB(=982(Q2048'N"/N(/?&L<B2*'C8,AZ$$$'[",B,776<=,!KR,T^FK
MS<-BDG-',VF5D9?2X:#:O)JT2=5:F;NHO.X2O1"3F8E)O39!1)`Z2*8@2%2>
MG4,F!B&&1[+M]RL+[HJT*U$1;)`Q)#.6.0""I_F*@#$+Y)N]I]3'LCR$HYU2
MHHJ^@`,$51F3(2/L6IKC0FGP,E9*AK+?5\NG\RAM"M[+0LNN[QU'V",I$O%T
MROU*-B=/+5#NW><?CB40H@LY*+J/:M'_`&.[2<H]@>["XB@N;8[?,L\T2&.5
M*,#(&<L2A;)Z5Z9,2,@0<1O=K:6>QN_U.U>UBGD$D$E581LBA55PN<>H#KF!
MW(I@=W'+^0E4)6)3E"M]CE\9J.82;]Q(LVR;9NG>K2U=WX\L14K!`9>.>IMB
MN2'!!M-++"(^TU4$'Y>(2PR+=>V3M*7#R@:3F=*GV])SR.>?5:>.(HW.1,CV
MB.OZP]JD!8MTHQU.2.U/_,3@E*/!.("'R0<XQVT:3F&:-KHKH5J!K'P:VFR%
M]K(P,Y(9W3;*9C)W6"9^8E)[H,VZD:DDW8F=>!2]1ZZG6XDNOKKE(;Z<I[:Y
ML(Q&VH!V6H0_97,U-,3';[5K:&S&W6<MSMMLLHED/I,S2J$9DC:C.OGE4"@P
M0O&/2:])-K!DT;8#S9\Y]@]45D0>-;`KG#Y99&`C;#%2R;6;C++1G"*D)((N
MT4U_%LV<'[_=%$63?-OGB]O<FCT),/4!33[@_$5(J"K_`(A0]R.V))QK=;:8
MR[4LFM[<C23748S^'4IH0R'T-E3(4)P4D@S2DF+N/7.X30D&CAFNHT<KM'1$
MG2)T%3-7;91-PT<%(H(D43,4Y#=C%$!`!ZC\;LDBNH]:D',5&1KG7KYCPQ*I
M8A-$T3$Z64C(T.8H:$=Z'(]CCE&^,G)N$KT_R#6KF)'918HNK\D+3FM?M_(Z
M=CIV295*(&?<*1</8;R_6DCRPH(`JJNU4^_4,0IO+N!>O5?R=N7,*<>L^)?4
M))+M<<K):II#2-IJ65!33V`;T]<>./BC;.#L>1WG-C!)##N<D2273U*QKJ-%
M+-74.Y7U=,&C\.-HFL6X]\D+=KUOE*+Q$8[?87O%JR[;.*P*:>3%/)?XR)=V
MY=!ZG5WR:34S$IA[++`N*11[CWAWS+:6N\;_`+=9;+`)>5_1*+U+=-7^,0IH
M0GYAGK\,JXG/P9?7.R\;W*^WJ<P\0^N8V<EP^FD0)%5+?E.17QQ(?I?(SC7O
M68[5EN?<RZ#GEF#,CO)K0:5?ZXG9LIB+4P;_`(+=04=2+5*/,!7Z(D$ZB*@"
ML4ODFH8H]5OMG'>1['N5GN6X;3/<6OU`"121MIF*G-,A4^/AET.+0W7E/%N0
M;3?;;MV]06\WTY+31R`/"&I1P2:#PRSSRSQ5GN[X#QKXS8*IJG+2!O<#*U.%
MA:EME]L#4TYLZJ#3W#6)BBV5>O9I5PB(&.=$''MI`455#"/F;7<=EWSD._WQ
MVW;&@D5R7MXP=-OG^$DT`\@:9]!C?:]_X_QGC5A^J;NEQ"\8$=Q(27G_`+U!
M4MX5\!F<"'S]^3RGY3E&&VWC-N>03SK3=_IM,G)DLA%V=-MF;:<68Z1-138[
M@&R1895N5JX>J$.FT%41[`?L(3'X_P#C.[WK=KZSY%9W,:VUA)*H&I?\336,
M-3^+J`.N(/\`)7RS9[)M-A=\7O;9VNK](G8T-(M0]PA32A'0Y=\2'73F'Q<S
MNG5._73>\P@*??$CKTB;=6N.51MZ"2BB2R]:;M%7#V;0051,50[=-0A!`0,(
M=5W:<4Y+?7$UM9V5Q)<0&D@TD"/R9CDI\`34XLZ[YIQ7;K6"[O+^W2"X6L9+
M5,@[E5%6(KWI08';F7><BY'?'ER6N.::)%WVHM\@OLW$VG-+P\13;V"KP;R4
M9)*RU6DVCQ%5F^;D%PQ<&`JA/X%DC$-V&1\-V_<]@^0=MM-TMWAF-S&K))&"
M2CL`:!P0:CHPZ=CB*<\W+9N3_&NZ7VT7*3VJ6LC+)'(PI(@)`)0AA0Y%32OA
MAV?%Z<ZGQZ\05%#G4.?$*>8QU#&.<QA:G$1,<PB8PB/[^N7R<JK\@[NJ@!1>
MO2G3"[XB+'XTV5G)+&Q2M<SU/CGB,'YR,7M=PT/AW8<&0+7^1<C9].<UZUQ"
MSUE.SA<BH+C3Z[5U562Z0/!%_$KE9D4*<I7"_B/\)S`-D_!N\;?:VV[VW(1[
MNP"W0,K`%4,L@C+@GIDP#'PS[8J/_<-M&X7%[LUWQRL7(#-(P920SB%/<5*`
MYYC+SRP:%*^2",T7X[8#E/4H]&1UZSLXK)8?.$S=WBO*";?MJ7'TK[0Q04*V
M4M+HDAV,4!+$]U1[``]H9N/QY+M?R!)QJ[)&T1DSF49CZ0#W-8/\OI_FRQ/-
ML^4(MU^,X^4V@!WR11;B+O\`5GT::=?Q>OIF,1<?"W*YGA]_YV7_`)1:936F
MC4?=&^5$V#2;*G$@[E7SBY+W!C#25AD2M6:=EF(07)T2"!U"ID_84`"U?FV"
MZW:SV+;^+6TIVZ:P,WLQ)4D#2$9@HK55-,\A4XI_X!O;+9KS?MRYC=1)N4%]
M[/O2O0!F+%U4DTHS#[<=&,]R8X^5BHUB_P!CVK-(&C78ZR=.MTM<81A7+.JW
M$2K$@I=R[3929DS!V[)'.(_L[]>;8./[[=74MC!:3R7<`K(BJQ9!XL*57SQZ
MFN.4\>M+2*_NKVWCLIS2-V8!6/2BGH<\,^^\V.)666EA2=$Y$Y/4+9(H1CI"
M#FK?&MG;=M,E3-$N)4/=.E"(R9%2F0,\,@"I3`)>X"'2ZRX?RK=+<W>WV-Q+
M;BHJJ$@E>NGN].^D'"*_YUP[;+E;2_W&WBN2`=);H&Z:B*A*]M1&'9?>3W';
M+7\?%Z+N&74R2E81_9H]C8;O`Q[IS7(V,/,O)XB"KWS+#IQ:8K%<F`$E"]O`
MQA$`%/8\:Y#N:-+86=S-&C!&*QM0,3ITG+K7*G;OA3N'+^,;0ZP[EN%M#*Z%
MU#.M2@%=0H>E,P>XZ8UU+\]^&4%$4V>E>36/MX?08QQ-TY^2X1[E"<A6CM:/
M=S*)F9W!VT2U?ME45'2X)($53,0Q@,40!;'P?ETLDL4=A=>Y`P60:/PD]%SI
M5C49"I\L-TOR%PF***5]SM/;G4M&0U:@&A;*M%\V`&"5IETJFB56OWBCV"-M
M50M,6TFZY8X5T1[$S40^2!5G(1[I(13<-7*9@,4P?4.H[=V=U874EI>(T=U&
M2K(>JD=01XC$JL;^TW*U2^L'66SE%5<&H8'H0?`XY=;W+8)5/ESY#5[Y3*?^
M8Z)J3"OL.)-NU)*0E<9J]9`B20LV3918L+#FD/=!NL_\!!B_15]\R?O@KUZ@
ML[3=[[X@V^X^,I-&X6KLU^D6D7#MV/34P7K3N*=:4QY%O;O9-O\`FC<;;Y6B
M:3;;I56QDE+?3QKE4"A`&K(:NQ\*UQ.1Q3XI8[P=AMQE<VNR<3A&E6QIK\3`
M3DN@I5LP1_*S&-GU(FY24HY%[595..1=(G<J`#5$H$!0Y``W5'<HY1O/-;BS
MBW""N^6T9@+*M'F]9*ZD4"CC-<AGY=,>@>(<2V3@-M?7.VW`''KF19U5GJD-
M%HQ60L:HW7KY#&3A_D8X/6.4CH.M<FLML\[+V>`I\1"5V>"9EYB?L\NG!0S6
M)CV**KF3;KR2H$.Y0*HV0*`F44*4!$.$_`.9P1O--MUS'#'&7=F6@50*DL>B
MY=CGX#"B+Y+X+/,EM#NEM)<22!%56-69C0:<O4/$@D#&_*[O.+6YU?VM7U?/
MY\^5*LTM*5BK9#/6=&5?-W+IJE9Y%%V9A$'4;LU3""JA1)[9@-V$.F.XV/>+
M40&YMIT^IK[.I&!DI3\`ZMF>P\,2&VY#L=V;A;:[@<VO^<5D4B+K^-NB].YP
M'O+FY8]R"XS1\]3^=[/C72%]'A73/><YN4(B2==4JQ+,)RC1L@K*1X2Z;Z2(
M*2R;150?>0()B*I>:9Y7QBQW;8>1/#>[,VX7JP-JMI4:B!TJLC``Z=(S%:?O
MQ#.6W^R<CXREQ8[ZNWV#7`TW,3BK%&HT:FH+5-1E7IG48!_>)>C8_P#-%QGT
M.UW5Q!51QQ+TNQ7&R6NURAJTFM'Q\C7VDPE'OGJD'!*OVS=`AR,4$"N5S`82
M&4-W&>[)!=[K\-;E:6L"O=#=8U554:@"=1%:5(&8JQR&6*VWZXM-F^<=KN[B
MY9+-MJD>1I'.AJ`*&"U(!.1(4"IP8W+K6,)Y2?'WROL&2ZG#Z%!5;*KZ^5EL
MWNLC'/X&U5F`?2\:TEE:^_C9F/52=M2G49N@*DY3`2J)G)W#J'<,VO>N-_(&
MU0[I;-#)+<QC3(@(9'<`E=0*G+NO0]\3OG>\[%ROXYWBXV>Z2XCAMG;5%(RL
MKH"0&`HPS[-D1AG_`!L<HN/D3Q8X9X1,;+166S3&+4U"/H$A/MTK*_?JPRDH
MG')IKF]L\PM'_P`XC45/NE$Q`Q2"!@[K/DOC.^/RW=]VM[2;]*2[<F0+Z`H(
M%<ORACU`H/'"3XJY;QU.&;+LUS>Q#>&M%`C8^LL:FA/345SI6I\,2R]Q_P"$
MW_+[_7]O_#_>ZJRG_'%ST\Q^W?$.&S\:+M%\MKQHS%5TXB=>CF\K$JYU]K6=
M:?DJ,+%,[)76D]+29(BTOXMH3[ME$JJ1IW,>BJ**ASMSE&S]NY';2<9@VT$I
M-;,0VL*T/J)TDKH++4Y%A4`]>N*0WWBE\G+Y-RC]<%U4@H66:@`UJIU`,5_*
M,CI&6+5S0:?-L)1OFVS\@;S8(EB]5M\7)JOZ3!YHFT:G<21-?G;.BV0J`LFA
M#J*,`2=22Z)?-%L=(Y51TCOK^&16OXK:&!J!&"QNTF>1B"K5JG\U0!W-13&)
MMLL;B%TVV[O)Y4C/N*=:"(`5(F9G]-.NFA)[=<``UJ-F"LP<&O2<K8TYA>D+
M\WU$M%?,9)9S)6>U11XY0"O5WT=#1H(.%4)`2*J#/HO2%:"HLD4UB27UD9Y)
M5N+IKMH3'[)=32B*=0].DFI`*"GHIGEBK!M][]/%`;:U%H+@2"?2X)U,0`?5
MJI0?B)(U5.)"/T_J<1]O#WW8.2E0T%ZF0:_0FGW=P>7_`+I$437RN9K@N8B\
M19TC%.*B9VZC)$0.\2:D`1ZK<WU],#):PVDEHOXI"$7V_P#U0RU1J_;7L3BV
M(]ILXE2*]O+Z&^:FB-=;^YX>R5?2ZTSK44'7#YXI81;HWDY<-.EUSECZ;1CT
MEX-F5;V71C3UI6C)I*MV"XQCP8=,T)`M&[M[&M0>I-5GC8GW1CE4*7GR+>[>
M3C<6VJ297G+C2`L6E!34JZ0WJ:H!-*@5`IA7P[C=[;\IGW6<@QQ0Z#J):74Y
MJ5+:BHTBA(SH30YXE4452;(J+N54T$$2'6666.5)%%)(@G4554.8")IIE*)A
M,(@``'<>JY4$M09L:#[3VQ;K,J#4WI45-2?W_9CFU^'?*<9WC_N*PVH4#.=:
MK0<Q[;)1;2WU^OW&-03E/S"W"6B#2+=\FT%\S,)2.FYBB=/^R<0#KTA\Q;CO
M6PGCD^WRW%I=?HT0JC,AJNG(T(Z'J#CRG\&[5L'(TY-;[K!;7EJ=XE-'56%&
M+9@FN1'<8`9DF='"_G!PRHOG.A<3,-,C*8>-B=*7&`SJ[)7-VS*PH$O*G?EC
M?LXM%5,/M5`\4VJ:@"'N")Y].P_7^$;[=+['++T'ZG0-+2IHK64"E<Z$Z@2:
MGPQ7=OJ_I_G>Q6A^HX;8A3:ZO4L4GNA:1$U`]-1Z?`8F+G^.>#U?X>[/.0>-
M9LQL4SP/B9&:GTZ5`#8)E^TSE.TM9.6F#1YI&2?L["[.^2754.HFY$%"F`2E
M$*?MN1;Y>_,,45Q=3M;IO+:5UMH6KE2%6M%!44H.V+LGXUQZQ^#Y;FVL[=9W
MV1=;Z%UL0NJK-2K$,:U.!*I7&S1]<XS?&KL_$_6Z/7N9_&CBS$VNK9!H!63^
MOZ#F5L*K$2AEV#D14B5'LFW48D?@4$3"KX'50,5)4)7=<FV_9N4<DV7E5K._
M$MRW)DDGB)5XI4-10C(@#,KU\CB'6/%=PW_A_&-ZXG>6R<SVO;=<=O(`R31,
M34:37.N5:9YBHZXT/O.V4/D7PSP.W1^#5["-(A_E'H=2WFAPS1%>$)KZ3D1N
MTC"++%4\(NPF!%1PV*(%!P4X*>Z;NJH_<=V2_P"-\TOK(WTM[MK\<EDMY":,
M8=-8PX\5KD?"E*=,1KDV_P"U\HX3MU^NWQ6&ZIR2..X15&DS:AK9/`,1F.@-
M<'[Q=BHJS_-#SK'5XR-<7/.,PS:)X_P\TS:&1KF5/FS!65?T2.<I>PR1?.G"
M8NEFA"F%1RJ!Q_C.`P'E,KVOPYLC[,["*YN9&NV4FKS"M!*P-30?A!/;R&+)
MXC!!>?.>^Q;S&AN+:V1;-6"Z4A--7M*13H<Z#*IP*ND-VE2YE?-'1\>209X^
M]X-O[?J,#`%*C4H?;W%0C/!R1FS\8QC9))@[D%'12%*JH<RPG]2>DIVQC=<0
MX=?;M4[V-YT0NV<CVX8Y$G,H"%TGITIB'[N/HN9<VV[8A38CLQ>9$H(DN"%J
M=(R#_BK2AZX._B?/\UH3@'P53XGYUQ_N\8XP&"/<UMKN]QJ3V/>D3;?@R<"A
M5X242>M7#8ZQESK&(8ABD`H"`B/4"Y=;\/F^0-\'*)[V!A>O[8@1'KXZM1%*
M=J8LKA5USF#XUX__`$C:V%TC6*^X;B1D(-333IZ_?TQ?;4]V:3Y'_$D]W^O4
M*K:LMM/(+\S0>93DO8J6T\,@LA(P8F6GF4=*.A6B2HG6!1(/!8QBE$2@`CPV
M2#:8MBY.NP23R;8MC#H:50KD&9:Z@M0*'IGC?D$V\R\GXE)R6."#=FO9PT<+
M%X_\LTHS9G+,CI7&&POXOK!DOR$:9LX3J`<35+*??,JRA%^!V,9R-MD4]K5@
MFG%>!,$F;>H1;U^K'+`/81D42E#R;"(*M\^3[?>/C^UV0Q$\I6,6\TYZFV1@
MRJ&ZG50!AY'QPFX]\176R_)-UOPE`XB93<PP`Y"Y84+%>@TU)4_9@-OC=P>G
M\F$_FBPZ],FSJ"T/D99Z]]PY;I.5(:5=2VF!#3S(%2F%&0@I4B3E$Y>Q@.D'
MK]>IM\E;Y><:;AN]6+$2P;:C9?F`]O4I\014$8@/Q7QZQY8O-MEO55HKC<'4
M'+TM5RK`]B&`-1YX=/#;0+MR<KV`\(-)K2;^^\`;=>9[D.RDHE-2-F'^#G6K
M/&E@4SIN+=5*WV&40D52%]520!A'^!3INYCM\/&[Z[YI92Z;#?HXQ;E&H0L]
M&NCD<M`!`KT+>6%G!MQO>5[=:<!OX0U_QUY6N=2`JWL56U45%"6:A/D!C2_Q
M_P"8;'RKXE;AD5:J^9-K+R!W3:V7-'D/J)V5HN]&6&49,V-1KN;F]N<F+F>)
M4.M%.G[AM$Q0^1R@=8H$!\Y[NFU<1Y78;M))<M:V5C;-86T/HCEJ*L[R#((&
MR8`%V[Y89OCO9MXYCQ/<MDBBMTO;S<)UW"ZGHSP@-Z$CC/JUZ1Z22%4=!EC:
ME\XR<=ZY\B'Q/X_7&-=V+-J_A^N5I6RV,T#>%+\;,64BSBCVV5;MUHZRC6Y1
MJHDDW5!1!B*7L$(4J8%!LVWDV_W'QURG>96DM-QDOHGT)J01^]0L$%=2E@0:
M@@GKAVW7BO&;?Y.XEL4`CO=LCLI4+/ID]TQ5`+D>E@#E0U`%!C:O*7C1?<)W
MK0N7_P`=ZN*VV0R;+8;+>2_#6<A(1O7QSN.BBV]NPK3-BFV)67,M75_OA:`"
M'W)@,JD98554#-7$N3V.^;!!PWGOUD"75R9K2_1F+^\QT#634N%:@K4TZ&F1
MP\<TXC><?Y%/S?X\6RG^BM/:O-N95T>T%UG2N06JBM!3N?+$I7`#3<MV+A_A
MVBXO0_TNSJP5=<\'G0',JWICAK-2C.<@6*XB)7,:QGD'(-E"@4AT/`2D('8A
M:JY]M.Z;%RV\VS=IOJ;^.45E[N"H(8^96E?/%R_'&\;9O_#++<]G@^EL)(CI
MB[1L&(917J`U:>6&G;Z[PT^3?+]%S2S,H33(BA7>VYU9FKIL>%T#+K_6WKF&
MD'T4HZ22G:R_!5O[K1T4/MG[<"CV53$Q>EFWW7,OC3=;?=+1I;:2:))4SU12
MQN*@'\KBAH1U4Y98;MQM."_*^TW6TWGM7*V\CQ/T6:!TR)7\R$','\)QRCW*
M\ZU3>)_)WA6ZTB<T?C#A?.W'LF2TD[U99!/,9B>M8RM-<RS=51M^732%?8NC
M-@4%LW<&,0G9)0A.O5MK8;'>\IV[F)MX[;DM]L<\YAZ'WE0!9`#T:A-#3,"O
M7'C6YW/?K+B>Y<+-U)=<5L=[AB$U:UA9FJA<9:<@2*TKY8FZ^3//\]J&P_$(
MA2:G5X2.B.6%5K$`I!1$8S20J9(R#4:Q+99F@GY11OM4E"I]Q3$2^7U$1&E?
MC;<=SN]HY<+^::21]M=VU,3Z]3&IJ?Q=JC/%]_*6U[39[IPS]-@AC0;BBKH1
M15-"$"HZKD#0UK6N,!P9JV?QVY_.)3GM?I[&DM=3;F?55U%0[>KMX,:;?':Q
MW,&J@2,2B15`ZANZ0)>0";I1S2YO9MEX/>(\K70M\GJ=6KW(QDPS+=O''#@U
MMM\.^\^LY$B6U6=ZH54)IT2FFGIIKTRZG$;DC`0+_P#_`#X8W,N8:)>2$%R>
M8GKTJO'-%WT.E)[K+,WIH9Z=(Z\>20:`"2OLF*"J?8INX=62LLZ?[@+R%F<)
M)M3:UU&C$6P(+#N0<Q7H<5G)#;R_[=+2[54]V/>5T-054-<$$*>H!'6G4=L2
MQZHFR=_-=P@9.R,W)0X>:859FX!NN!5BIS3A$BK97S\5B^U[A`,7R_A\@^G?
MJJ;#W8_AC>9(M0/ZQ'F*C^W%M;F(9/G'8(Y`C`[,^1H?RCL?[,!SKR3**YK_
M`#3M\\*T89XIP/57TQ.),BUKX:RYJ+/\/%\1N)&(69RBH]\@'_$',9;OW$3=
M3'9_<GX9PT[D"VY'>?\`!)J7,`;,#OI!I0],0C?-%OS;FR;65CVC]'/O!*!!
M/HH">VJO4#.N,]R`CXX/@3XKRL`S9!J:2W$I?(W\>W;A8QTM33ZLS;FK[IN4
M'QYL\$1ZF?VS>X*!#@/H4>R78Y)'^==UM[UI/T@I>"<$G3[7L,?4#D!JT_?A
MQWZ*W7_;[L]S:+%^LAK,V[*`',WO4])ZEBM:_NQT9=[[^XG_`-;=_HC_`//?
MW?W/_9UY[IMO_P!S_P!G'I+5O/@W_P";7_Y'A_-BC5*.ZO-3790[M*+ML*_:
M6FB3BH"9.%N4&8[B'=+@0!4/'/!,=F^3#_G,'*Z?^_TBV^Z%I<ZI5K:N"K@=
M61NOWCJ/`@8<MULGO;73"=-XAUQM_"Z_A^X]#Y8B4N>_-]%=:;E#.42H3R][
M*P>;$O.*D#]/F,!G5!CYNKODC=QD)`DU!.SE;I@?\108HH`0Q)%+RLVWV26R
MM[?=9%$L45J1#0UUEI'*MUH*!@*Y4))['%,7W)$W&YN=AB;V)[BZ4W!(-(PJ
M*&4TSS(Z4)H!2M<R,?1$>X3F#2&):3$<;I3'H#(XZQ&C2N[K"C6IZ8L#+1I'
M-D@5NS.#0=/DG:3X[=23*[;BX79)I&]SJ-QRR"19$NHFWQ+AI2*T1@P`T!SZ
M2V1%*TID#7$MFMHBCK+9SCC4EHL.JFIU*DLLIB'K"9ZM76N9`&6!]H'(5_6Y
MK'LL!W&W71:'.:34LC_#G8OX:^-;#32Q]1*V?(*'4&$KZ[I-=P8P@LSKYD#+
M=EB+=I%>;$)K6ZW4*T6W3)"\U<F0K(=67<M3+KZJ]J8B>U\GEMKNTV0TN-TM
MFGCA*YK('C`2N50%/7OI%,2UYA1&^<TZ,K1'RLO(D,[E+'8')2D>66U33I24
MLMB>@7N!5Y>7<JJ@0!$J*0D2+_`0H!6=[=F]NFG(TH**H_A49*H^P4^_%T;7
M9+M]FMO75*?4[?Q.?Q-^_IY4P]G[%I),W4>_:MWS!^V79/F3I)-PU=M'21D'
M+5R@J!DUV[A$YBG(8!*8HB`AV'I,KO&XEC)$BD$$=:@Y?NZX6RQI-&T,@#1.
MI!!Z$'*GWXCE/\2W!AK+3TM4LLL.9#:RBE:(K*-6U'-J]86YC*&,TEH&H6Z*
MBW#,?=.`)`D5,I3"!0`!$.K!/RES6:%(;VXCN?:'H::*.5D_E9E)!Q5Y^'.!
MI/)/9VTUM[Q]:PS21HW\RJU*8W*KP*XF&PO_`"TL\9@83$%)`DM(4&N2,_7&
M$])$`>[NS/X668R]F57'Q%7[]PX!02$$W?P+V:%YURP;X.2&[=MX`H)'"LRC
ML$!!50/[H&'UOCGAYV'^F4LTCV4MJ,:%E#-XNP(9R?,_9AUNN(V#O<&2XR.J
MA(+8@DT)'EI1[I=O`8E-<RY(-2:"PA8%8(OE[?V1G0M?8`$O#VP`O25>5;['
MOIY*DH&\5U>YH2NKIJTZ=-?.E:YX6MPOCS\>_I5X6.QTI[>M_P`-:Z2:U*^5
M:4[8TFX^,7AT+2E-8K/[555<WK\O5:!*5#6M4K4[4*Y.R",G*0<).1=P0E&L
M0Y=(AV:^Z9NF43`0A0,/3ROR1RT2S3RSQS&XD$D@DBB<.X%`Q4K2H\>I[XC[
M?$W"PD*0031&",I&8YI%*(34J&#5TDY@9@8=4W\>7$6>P2/XT.\A8M<EBK0A
M>F$5&3MCC9U*](.%'0W8]Q:2R=J<VIRLL<5GRKLZZH'$#"(```EAY_RV#?6Y
M"ETQW)XC&254K[9%/;T$:0E.@`IA9<?&?#KGCZ\:>S"[8LONC2S!Q*#7W-8.
MK6>[$UQ;6;X[.)MIC,_:.LZE8J;R^,>PU)T&LZ!?ZWJD5%R;MT_E&+C3(FR-
M;G--9)\^6663?/'!#**F$`#OUBVY[RBVDF*S(UM<MKDB:-&BU`4!$170I`RJ
MH&-+KXQX?=Q0(UNZW-LA1)ED=9M)S(,H.IJG^*N,W"<!^*==QZW83#Y4W99U
MH4C^,:(T1LEL)8]"E#',==Y>;J2<+;[2=T)S%5*\>JIJ$.8IBB4P@.DW.N53
M[M#O4ER3?6RZ8?2NB)?!$TZ%IVH*^>.\/QQQ"WV6;8(K2FWW)K,=3>Y*:DUD
MDKJ>M<P33RQNG%<.S7CU0HS,<CKZ]5HL(JNI#5X\Y.SK:)(X$HJ-(Y:PR4H[
M9QY!+_+;)J%02]?`A>X]V;>-YW'?]P?<]V?W;R0U9Z!23XG2`"?[?'$AV+8=
MLXUMZ[7M$9CL4%%0DD*/!:DT'EC6>P<+>.6\Z)5=7U2AO;+?Z,1J2GV!*[7J
M#5K9F:ZKA-Q#LX"RQ<<Q>*G6$JRZ:0*KI]B*&.0`*#AM'+N0;'83;9MLXCLI
MZB1="-K!'1M2DT'8=NN&K>N#\;Y!N4.\;K`TNX6]/;8.ZZ".ZA6`KX^(P24U
M"1\_"2=>DR+J1DQ&/(A\FW>O&#D[%\V.T<D0D&*[=^T6,@H(%624(J0?XBF`
MP`/3!%-)#*L\=/=5@PR!%1F,CE2O;$GFMXY[=K:0'VF0J<R#0BASZ].^`XRO
MA3Q/X=OKML6,9)*U2?-7)M]:!K-@T&U2UK;-TE95VD:M/K!+I6:QNU43`V,9
M!5X9942IF`5#=Y;NO,N4\P2WVK>;I9(%95C+K&@CK1?Q!1I4=\Z4&(1M'!N)
M\'>YWO8K5X[@QLSA&=S)2K$:235B>G>IQK_X[Z'<GL!LG*?6LZ=9?KW+73GU
MZEJ/*PX0EAIF<U-N6F915K`R.DDX3G25J+&0?F4_F*.GYQ-ZATX?(&X6RSVG
M&-KN/J-KVNW$:R!M2/*WKE92,M.HZ5IT`PU_&FVW<D%]RS=[<VV\;M<F0QE=
M+)"OIB5@<PQ`U-7,DX?5Y^.CB7?-%LFI/\[EZ[;[R<I]"<YWH.@9M&:*;N/F
M>]P=&LL%$V55<!$%5'")E%?(WF8WD/=OM/D#E5GMT>U^^)+.$?X0D1)#'Y1E
MU)7[CASOOC'A]]N4FZFW:*\G-9?:D>(2]ZR*A`;&8>_'[Q)>WW/],+DC6+N&
M41\3$9J_KUGN5<94>*AB$(UC:S"05@CX6*8+@0?NTDFX$?&.<7`*B<PCSBYW
MRN/;KC:OJB;*Z8M*"J-[A/=BRDD^&?IRI2F.TOQOP^7<;?=3::;RT6D15W4(
M!T``;]_CWKBQUGX]^+^U7^WZC=JC:4[QH,5#U^]S%2T[1:,6Y5R"C_PMA7[(
MPJ5FAXV7AP8?RU$5DC`H41[CZCUG:N=\EVBQBVVUDB^C@=FC#1(_MLQKJ4LI
M8&O2ARQSWCXVXMOE_-NEY',M[<*%D*2O&'510*P4T((R.73!44*@4[+J=6L^
MSRMQ50I-0B6L'6JU"-B,XJ'BF9?!NT:-RCZ%+ZF,8PF.H<PF,(F$1&-7U_>[
MI=R7^X.TMY*Y9W;-BQZD^7:F)=MNVV.SV,6V[9$L-E"@5$7\*J.P\_$X""Z?
M%APMO5WO>DR6;V.&OFF6*2LUYM5*U'2J+*6)[+)HD?LI`U3M,0@M#K'2%3[4
M2>T5550P``G-WF=I\G<QM+*#;1/')86R!8DDBC<)3H1J4FM.]>PQ`[[XDX3?
M7T^Y&"6*^N9"TKQ2O&7U=0P4@4KG2G4G/&ZJQPJXM4[")GC/`8G2FF'61)P6
MR4-5BJ\96)R[.@JXE9Q^\7<2\I."NV24*^5<&=)G2()#E\"]F>[YGRF]WR/D
M=S>S-O,=-$E?PJ,@JC(*H!/I`IY8?+7@?$K/89.,V]E$-EEKKCIDQ/YB>K-E
M^(FH[8AHYL\5Z7Q]US@)%\?\EY!VR"SGDE6=5TV1C&>T[@QJ&<U]!.(CD&DM
M*N+.WC&L3_.!&)8G(L"7\8IB'@(W%P;D]SO6S[\^]W5E%+/MSPQ*?:A:25JD
MU`"DDFE6.6*(^0^(6>P[]QV/C]K?S16^XI+*U)9U2%:!0#F%IGZ1VQ*W?OCT
MX=;'I<GM]SQQN_O%P8QI;>\;3]SK$?>FC5NB5@C?JK#3D3"V<4&Z9"'2D6JO
MD!?%4INPAU5=CS[ENU;<NRV=T19PN?;!5&,9[F-V!*_:I^S%R;A\:\+WO='W
MZ]LS]?.@]RC.@E';W4!`8TR-<\81;XP>$:^;I8^IC`_I8WLZMR;9^2_Z2G56
MUD6`?*4;0Z=M(T05(H(J$(4H)D6$5"E`XB;KNOR5S/\`4SO'U9_4VC]LRE(R
MY2E*$E?N\<<3\2\$;;!LOT7_`"H2>X(O<D"!CG4`-VQ7H/QD\-M*L57NL_F4
MNQT&G0\3`0&D5C2-&K&A-XF#8!&139S<H:TM9V1491_\@JSA9584A\3'$/3K
M&W?)'+]LMI;&WN%.WSN6>%XXVB+$U)T%:=<^PKC.X_$_"-SNH;^>V=-P@0*D
MR2R+*%444%@V=!EA]5_@7Q+K>/7+"&6+5Q[FNCR1)O18N<=3,[,7V>36(Y2G
MK?:Y62=6F=F4'!`.FX7>&.D;N)!+W'N@FYORJ?=8-Y>[=;VV6D)6@6(?PHH&
ME5/D,^^'&W^/.(6NS3[%'9HVWW35G#%F:5NS.Y.IF':IPQ\E^,[A[BEII]MH
M^=39G><R#R7SB%M6C:#=:=G\P_1<-W,O3J9:;+*UF#E/:=J>VX2:^ZB8WFF8
MI^QNE^[?(_+=ZMYK>^G73<"DK)&B22BHH'=5#$9"HK3QKANV?XJX;L=S#=V%
MN^NW:L222/)'$V?J1&)4',Y]:X/7P_I-_P`OP^O^O^]U!-`\!^&G?]O_`!Q8
MWJ\3T\NOC^V6/3K?&<1^Z]_V_/UHC_U)_)?ZZ?>2GVGY;_.7YT_&OL*S^*?=
M?IS_`(C\T?A7X3Y?<?\`4/M?M_'^7X=3S:?Z[_1G_3O=_1*"NKVM&FII_F_E
MKJZ>FM>^*PWO_ME^O?\`-O:_7]7Y??UZJ+U]G+533USIC+%_RD>Y_#^K?N^7
M[/\`-=Y^7?\`H]?+OTF_ZGR_TOE_HL+/^B=)_P!5IKG_`*[]J?V8M,$_R"_J
MM._HG^1?UD_$%OQ7[[\T_G?\9_!I#\1^Q_/G_4OQK\`^X^_^S_Q/VO?[C^#M
MUWY!_77Z8GZY[OZ5H733V]&FOIK[7:OX:]^F$O&_^V?ZTW]/^S^N:C7_`#M>
MJF=/=[TZTS\<'J7Q_P!W_P`_]?KU!<68-/:G[>'EBKHQG"Z,&%T8,+HP871@
MPNC!A=&#"Z,&%T8,+HP871@Q\'MV]?\`3_P]>C&#3OBD/#R]._E_3Y?U_7K1
M=&HZ?Q=Z?M3&1]],5];X,+HP871@PNC!A=&#'P>W;U^G]?\`LZP:4SZ8P:4S
MQ3_#^SO]?V>7U]/KVZQE3.M*>>!:?EQ4';U[?U_7_;UG*OG3&%IV\<?>LXVP
..NC!A=&#"Z,&%T8,?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g908511ex99_1pg001b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g908511ex99_1pg001b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-@!F`P$1``(1`0,1`?_$`)8```,!`0`#`0``````
M```````("0H'`@,%!@$``@,!``,!``````````````<&"`D%`0,$`A````<`
M`@$$`0,$`P$``````0(#!`4&!P@)`!$2$Q05(A8*(3%!&#(C%S01``(!`@4#
M`@0$!00#``````$"`P0%`!$2!@<A$P@Q(D%1,A1A0A4)<5(C,Q9B<D,74S48
M_]H`#`,!``(1`Q$`/P#?QX8,'A@QQ[9.06'<>:\-KW+6:!E,`('%!_>;1$P'
MWS)B4#HQ35\Y2>R[D!,'_4U365'U_P"/G.N5WM=GA[]TJ(:>+YNP7/\`@"<R
M?P`)Q,ME\=[[Y&N/Z3L2T7&[7#XI2P22Z,_C(RJ5C7_4[*OXXXQQ@Y_\2.9=
M@OU8XW:_%Z3,9JC%.[2V:0]DA!383*KMNRDXL++#PYYJ,^RS,DJX:E5214,0
MIS`*B?NYMCW;M_<DTL%FJ%FDAR+`!EZ'/(C4!J&8R)&8'3/U&)MRGX]<O\+6
MZWW3DNS2VRCN9D6!FDAES:,*623L22")]+!E20JS`,5!TMDY'DCPE\2X["NV
MSB_UYQ_X6[R#K1=JD&"3^`Q*D.V1K(+5S_\`'*W"3<"JPH\"Y`!,FLY(JZ<$
M`3-FJX`80@N[^0+'M!.U5$S7,C-84(U9'T+GT1?Q.9/Y5.+5^.GB#RGY&5/W
MMBC2V[(CD*2W.I5NSJ7ZHZ=!DU5*/0JA6-#TEEC)&<)I;^1?SAH&E9;([%PG
MJ6=XUJ*S&7KD#,1>F1&@VBBKS!(MW.TZUSS^/AII9$3B""P00-7"A0*`%*<#
M`K).8]T4E;`]QMD<-MGR*J1()&3/(LCL0&_`Z,B<7WI/VV^"MQ;8NM-LO?%9
M<=ZVH-'-+')124D%4(]:Q5-/$CR1`_F4U7<09GJ1D=CJ9P5335*!@!0A3@!@
M]I@`Y0,`&+_@P`/]0\L8#F,\8OLI5BI]0<L>?GG'YP>&#!X8,'A@P>&#!X8,
M19[D>T1]U_YO4J/D<4TM')W;OOM<YC7C(TM'U"%:KH1SN[R<.F!C33Y24>)M
M(>/$/C>/`4,H!TFZB2JUY'WRVTJ*.EMZB2^568C!&811T+D?$YG)%^)S)S`(
M-W/"[Q6@\AMRUE]WA,]+Q;8M#5CJPC>HD8%UIDD/]M0BF2HE'6./2JZ6D5T1
M+B=T.V+>W;'DYVOZAHVQ[#<T4)M7'CVU^U9UELZ,F[:P]XL[%8DD=VV1-[#0
MT$>,CHT1^$JBP%$I8K8.*IKLPO>_IYJFXRC5V=9`4'J`[#KF/Y$TJOIF</SE
MSS[MO'\,G%WB3:K99MFT3&(7'[=6:=ES5I*6!QHTL>HJ:H3S3?650G,Z!,)X
M@<7>,9%AP'!<PREXZC_Q3Z:J-4C&-EDXWY47`L9>TG16LDNU,X;)J"1RZ5`5
M"%,/Z@`?&W:MNV*R?^II(*=B,BR(`Q'R+?41T^).,\M^\R<J\HD#D+<%UNT"
M2=Q8JB=V@1\B-4<`(AC;)B,TC7H2/0XF5W#=M$5P4J+7&\7%C<>7FF1R9*I`
MI-RS2&9P\LH9BRNMCBDBK"^FI!R(IP428HB]7**RI1;I@1Q".1>0(]K4XMMM
MRDW#./8OKVP>@=A\2?R+\3U/09&T/AGXA5?/=X?>F]NY1<.VN0F>4GMFMDC]
MS4T,ARTQH.M5.#_34Z$(D8M'.7B%U^Y'PKSV>[1.X*U$L^SS3D;U`T'0W!;5
M)P=FE0_(0X2T&^.JK?MQF52E^I&>AV<$4`$X%41.LSAVWMI6_;5&^^>1)-=R
M8ZUCD]Q5CU&:G^Y.?@OHGQZ@E;*<Q^0^\.;MQT_BMX:TAI=DP+]K+5T8["2P
MI[).W*@`I+9&/[D_22J/1<UD5)^0\/<JVGNZ[#?]]=SJ[^J<2,,L46AG=8DC
MJJQDL%*DSS%,RV"5.1-";,G,K?E[:^2+\!EE3M2^WYTBH\[;M!<^3MX?Y7=(
MS'M^E<=M3Z'0<TB7^;K[Y6],R5^(RF/,V[=D>#'CE_\`/^PZJ.KY@OU,YK)T
M`#Q_<IVZFNE&9,6<8^WM\1.H*HE.?;<OLLE9:+@HU],S<E'PT/&-5GLE*RKQ
MO'1L>S;D%1=V^?.U$6K1J@F43'44,4A0#U$0#RQ\DD<2&25@L:C,DG(`?,D]
M`,8K4E)5U]3'14,4DU9*P5(XU+N['H%55!9F)Z``$GX81ZG]GW`"_P"M1.&T
MKE3E=GTZ>E@@8*!AY)^[8S4V<YDD8B(M:<=^SY*2=K%^-!!%^=1=00(F!C"`
M#&*??&TJNX+:Z:O@>M=M*J"2&;Y!\M!)]``W4]!A[7GQ:\A-O;1FWW?-IW6E
MVO3P]V661$5XH@,S))3E_N$11[G9H@$7-F(`)P^/DJP@<'A@P>&#!X8,'A@Q
MD?\`Y"^(;5G7)CBUV*T6G.=$SS%V5)BK?'_5<R,74I[.=)D=!@'-I0;)+*QU
M4N`3)FAWOL%%!PV]JABG61`]?>7K7<Z.]T&\:6,S4=,$#C+,(T<AD75\E?5E
MGZ`CKU(SV!_;GWUL?<G%^Z_&Z_5JV[<=[>JDIWU!)*B*LHDI)1`20'GI^V)!
M'GJ9'S4%4D*UHXX]XO77R"J<1+R&Z5[$;>Y;-_S>?[.X_9LC"29T$CN6C:QO
MDR5&P,TUSF*DY:/3"J4`$Z:1A%,K`LW*&S[O3K(]4E+4$#5'-["I^6H^QA\B
M#_$#TQ4/DKP2\D./+O-1TUAJ+[9U9NU5VT?<I*@)`8PJ341,1D622,9$Y*SC
M)C\OF[W2</N-.#VZZY1L^4;UKZS48C-\WH-VAK6=[9I%-4C&7M)J^^=&BJA!
M>T7+U4QTSK%3!ND(++$$/7N?DK;MEM4E305-/5W'+*..-P^;'T+:2<D7U;Y^
M@ZD8^O@OPBYFY.W_`$=DW=9+OM_9H?N5E95TTE/I@0@M'!WE7N5$OT1``A23
M(XT(P./7A;R\".Y(W?E9=\2T3G)SRN-G<2N/5-=@X?42LVA^!/FT:=CX-O+V
M:PS$(51-G`Q#!FS91+9`3E<HJ%:BWKMMK<.B\RWZJI9KINN23.%",T5C_P`C
M!<V8KT"(H"H!GJ!TZ=EN;^'?N.-*'B6Q7VV[$X!HJ41W&H5@M5-`N>5'$\IC
M@ACER:2JJ)9)):AVTF)U,W<N5G/5MR^[!=7JG(_N)UO]CU!1^FCG?%R#G6,`
M^6*Z.FX0JS9@QD%8C/X]\0H`Z2:JR%G?E+[7"[=4I5`:-'L7<.[J^.\\BU':
MI\_Z=,K!3U_*`#E&#\0-4K?$@]<4/W)Y5\.>.^T:OC7PRL_WUX$9-9?)8FF0
M:009V=D$E6Z?D9Q%0Q$YQI(A*8TG6BR8%PJX]R%@DR5?&\$Q"G@8K**8HQL)
M7X&-(5%E%0\6S("CV3DGBI$6Z"95'3YZN4H>]97U%T3S6G;-H,S]NFM-+'Z`
M9*JCT``]23T`'5F/Q)QF7:K9R#SAR+';Z4U5ZY`OM;]4CEY9I7ZM))(QR5$4
M%G=B$BB0GVHO3)Q9="Y,=YELT'0]$T&1X<]3F%R#Z2M4T^?$BDK&P@`%TK^6
M<J'+'7705V)BJK`J*\+7`73(FDY=F(#Q`S5E[Y1J)JRLF-NV#2DEF)RU!>O4
M^CR9=3GFD>8R#-EJUSMFW.,/`^T6[;FW+='O/RXOT:I!$J=PPO+[1VU`UTU(
M&S5=.BIK-+%WBB#=CA'`3C+@W+'L13Y#X-G1<&Z\^"JM?M;V_7*2D$WUYE\O
M,YLE<LEWL=@?&13MUPGD`G91,#)-XBOM$T#D24,C\G*VG9+5N#>'ZQ:H?M-H
M6K2YD<G-S%FRL[,?K=O>WH$C`!`.6<_\@N4-_P#$/C@>.-_7+_(/(S?HF@6D
MID0K2QUVF":&FAA3,T]/$32P$AGJ*N1I%9U#Z:4[#W!<LN9FCZ!DG594*S6,
MIRR.DY;5>9>PM&K.H5JOQ31^YD+.B-D:N:[4*W]9DJJU,^9R<S())&529-RD
M./DUN/(E_P!R5DUOV)&B4$"DRUDP`15`)+>X%47H2-09V`S"C(XK'LSPVXBX
M5VU;MX>6%9556[;M*D=!MRW,S5$TTC(J0'LLLU1-FRJXBD@IHF8*\\A9<=&_
MCZ<T.:G+Q'DJ?DC?3:OGE`?TYC2[X_KD%"OBVZ7-.+3D!'O8&%@4Y.++"-&C
MLR3A`5F8KH^@E!<2^?9Q'N7<NX16F]2_<4<)0)(553K.K4H*JN8T@'(C,9CY
MXCG[B7"7"'#K[8'&=O%HW'<8ZAJFE2:65?MX^T(I76664H_=:2,,C!9-+YYF
M//&DWQT8S*P>&#"N\EN:G%KA]%1TMR/VFH9@6:376@XF45?2=GG46P^Q=>%J
M5?92UFDVJ*GZ#K(M#(D.(%,<!'SA7K<MBV[&LEYJ8X-7T@YEFR_E106(_$#+
M#5XQX1Y6YEJY*3C6R5ET,!`ED0)'!$6Z@25$S1P(Q'4*T@8CJ`1A.J-W9=6F
MNOE:BWY-U.-/+`>+49Z94+M2("20>%,V5;NI>Z5:-K/U')%!(<KER0IBF]#!
MZ#Y':7DS8MP;[<5L:ZNF4B.BG/IU+H%R/XG#FOO@[Y6;/@%XDVO5RB')PU%4
MTM5*A7W`K'33O/J4C,%$)!].N%H[`N*72-C^,2_*/<\*RI*+G$UWE*3Q>Q2E
M,D]<L;M(SAG#42)S>S0==FG$DH8#KNR(BU:(B9PNH1,HF\XF[;#QC;K:U]NE
M+!VVZIV6*&5CU`01LJG/XG+(#J2!AH>/'+7G-O+>\/%6Q+]=C5P$+4FY0QU*
M6^%3I:2JDK8)9HP@Z+&6[DC91QJS$#$'^I3JNC.P#>9WD[?LD)D_".KW-Z_K
M&:)2EBDV>@OV#OUC<VAK#/O%[#.U*`!(@6"7.L!G:H&:HB1117ZBJX_V&F[;
ML]\JZ?[?;$<I*QYL1(0>D89CJ9%_Y'SZGVC(DZ;]^7OEA5>/'']/Q9MZ[F[\
MY5=$J3UICA1J1'7WULD,*B&*HES/VE.%RC7*5]2JG>V06'_3/KLQ>RZ.I5LA
MXW935611EGE4J-?JIY5P;W"PAFC6"CV\I:[)++D]C5J4'#MRI_8!]!$+&S?X
MWLZVO6F.GHJ",=2B*N9^``49NQ^`ZDG&+EN_[K\D-[4NVEJ[SN;=E6_]-:BH
MEG$:_GD9I7,=/#&.KR'1&B^IZ@&+^J8#A?\`(<@\7Y+8QONP8;&X/89:AV^G
M3]`75=MG*T@PLBKZM/"6%E76%R%H"!DY1BYE4BHG0(NFDJA\9EM7VFU\OQ4U
MZMM744J4CF-T:/J.H;-3J"A\LO<I<99`@$98NUM/D+?G[<M?>^,=[;?LU^J;
M_31U5/4158"L`CPA9U,+3/3:M8,$J0,6$C1LZ2:@D?>[RFK6M<L,?Z^K3K3_
M`#3C;BK>LW3D7=0^W-S,O/KP`3A&Z44S347M5H@Z*HF2(9B7V.9Z9$5O85(%
M$XQRI?8+A?Z?:,]08++3!7J'ZL2VG5Z#ZF5/H'QD?KEEF'IX#<473:'$5Y\B
M;59X[GR9?&FIK/3>V*..(2]K/N,0(():H$U$F>:4M,-&HL5;\KG6:<D^YXM`
MP'`J7+<..I/"'K*#B2BA[7EW+`+^JTE)*E,1'3M2D5C*.#I@=:&A7K@[AVLX
M>C[W'HHZ*]<D]FTVF)K;Q_2D*/F^GXG_`,LI]?BB,26);JW4W)N?C/PG-QY"
MY!KH=Z>7M_1I9.OMIN\.B1CJ:&@09(#DM14Q(L<*1PC3%TOMVL&?8='<;.F#
MBK.U;C]D<LPBKYR)O4]+EC8UI6%W;EXWD-*L1O@=3BAVT"]LTX4PF=21T8]N
M@3VBFW'[>0IJ.UI1<;6%XZ2WL`]0['(!<R<Y&]6Z*TK_`!;)`!Z#$9\/+=N/
M?E3N?S9Y8IZO<6\(9)*6STL4>MVG"JI2BAZK$-4L5%2^B0AJF21L]4@XU48O
M0>P2JP/6GU:4Z9R3@%G<DP+R(Y0VN(<P\IML\0[9:5M=W<)D:.GQIE=H#J.K
M*:@/GH$;_;!DQ;D2;<VGCJ]W4Z;*V+&U/M.%A]Q4N"#,W3-W]"<\LUB'N/35
MI4`+-+Q5[=\>+O4>3OE96P7CR#N43_H]CIY%DCMD1U!*>E!+*O;#=N:N8=J,
MF3M&>>1GET:YCH'7EU4UO"^#2FP4O-;!8_>$2RL\@G^X;19)-,JDA?=-F&;<
M8RKN+C))@DU=2BC)HH()M6OHB@4B;DH:O:&PX:7:YJ(H9G]`Q]S,?624@9+K
M/0%M(]%7H,AFQNG;WD;Y9W._<\+9JZYVZF_N-`A[,$*')*2AC9M<XIT):1(!
M+(,VEF]\A9J4VBV5>DUJ9N=PL,-5ZE78QS-3UEGI)I%0</$,TA7=24C)O546
M;1F@B'N,H<X%`/\`/DTGJ(*6!JFI=8Z=%+,S$!0!ZDD]`,5DM5HNM]ND%DLU
M-/57BIE6**")&DEDD8Y*B(H+,Q/0`#/$X:5W#<"]`R#9MQJ^K2+V@8%;J;5M
M/>*U"?:R4&RO^A0N;U*[H13AH1U)T>7FIQ-<KMN"BY&:*QCH%53^$8;3<B[4
MJ[=4W2"H8TE)(BRG0P*B218T?++,H6;/,=<@<QF,L65O?AGS_MW>-DV)=;3&
MFX=PT=3/0J*B)DE:DI):VHI3(&*I4QQ1%2CY(9&0+(4;6(>]J'$#DK1NS)CS
MIDN)3_G_`,:GD-6TO_*6A)>?1KB<#3DJTO6)VM0;.;EF;..GS*3C!48Q]$.E
MUQ*Y(9052BL-][=O5+O8;I>WF[64JO\`2&;:=*:=+*H8@!LW4Z60D]1GGB]?
MBAS)QC?O%]^!:;=\?'O)R3S'[]C'$9C+4F<3Q32M%&S/%II95[\50BH#&P4(
M<+9R*L[WFM4WN>81_'QF,[N<@P/'QNG?M2W4!Y4GIR^QO(-G-1S_`">#="Q5
M'W`66D%60_V51,7U#SBWB=MS4YH[5M%H:EAD)=#QE#\#FD<2G+_6Q7YC#-XW
MM<'!]WCW'O\`\B(;E9(I-;T/W%-5K4)^9"M167"5=0Z9T\*R_P`C@Y846S=*
M'9MCU5RS2;OQ[0WJE5F5"7D,#KFCN;;+P$:H_1E):`F:U59AA(LV5J!J`.S5
M9V\7`1]53)J``^1Z?C/>]N@@K:JD%73(V9@60N5&>95E0@@-EU[1)^>1PXK7
MYP^+N\[K=MLV+<3;?OE5#VTNLU&*>.5PICCEBFJ(W1F@U9QBNCC3+H@=<\6U
MSWN'YMQM%KF+X=TMZM4[768AI6:[7T([1(C,:PVCT0;-4T80,EKAV44W`GK\
M*DFV``]1,X$?4PLVCY%W,E*EMM>VIXZA%"JN4@B4#H/;VER'X%A_'%&=Q^&?
M!M5?JG>^^^;;366FJF:>:8O125L[.=3$R_J$VIS_`#+`_P`,H_AB=78MP6[I
M>3&6L>4_)]@>\/HZQI-H?BID8JV*0R>IR,2X<+6IE1ZH>5B%3).4$FCL4'<U
M.""H'<J@FF8"0[>.UN2KW0"^WP=U@_2EB]QB0CZ@B9CUZ'(N_7-CD.EDO&WG
MKPDXOW7)Q1Q;(*&"2F)DOUPRA2OJ$D`$#551VY!FI,D>N.FI<U*Q)J8:G)X]
M\U>S;_7W+^*_7_U7S^%(4RIPM2<Z?KS.=3KS2<^),+'<TPO$!FE9"7FI<SB0
M76D',J8ZRQQ,@J(>@R2S[EWM^D06':5B>E$4:H990VD-^9_>L2YL<V)8OU)Z
M'"5Y&X0\7O\`L2Z\L>0O*]/?Y*VLEJ%HK>T7>:+,]FF/VLU;/VXH]$*+"E/D
MJKE(F>8G3R*ZU.?O'KD?3>5O+3CVIV+Q=R=H7K8HC-Y*W2K*0LGU#,3U*X'I
M=>96.*2A"(M#H+-HI2"<(HE;>AT2G2\AMXV5NRSWJ._[@H_UA)#KF$9<@MEE
MH?0H8:>F1"Z"!IZC,8LGQOY.^/?(W&=;Q'Q#N(<;55$AI;=)6I3QLD.K5]Q3
MBIF:&0RYR!E><52LQE.ERKXKY`=I'9=I-7A\TX4]/]ER5I&QK>`@)+3FE@B,
M]J+<A`;M4XZ+>U7&JNQ8QY?U$*:0!+]/]4Q#U`6)#OK>M;`M%MG;KTZJNE3(
M&$:?+(%(5`'^[+\,4WN/BIXQ;9NLVY^<.8Z:\32RF65*)H9*NH).;%W2HN4[
M._H2(=77ZAZXCAS8X!]E<'R(I_+/FY@$GS$9WQY`S>HUS!7\PNT;1L"5*'0R
MZ9>9O63RE&!K!,FY$7S!DZ9"0?TNEE@5'Q<;FVEO6*\1[@W/2-<5E*M*L!.0
M"].T3&N:9*!DRJ5^3$YXNEP=Y">,=?QO6<0\&[ABV9/0)+%0S75(PS/+G(:Z
M-:V?15:I6<M%+)'+G]42(4&*G4[E%VN;?GD'Q[ZY^MQEP#R=LR-#H:!HL>I"
MDK#%5N*3R1A'5UJ].B4Y%0Q_D6=I0L_*+*?]I1^8??Y.Z>^;]NE&MHV=9A::
M`#+N2#+2,NI!=4&?S(21CZ^N*GWGBOQ*V+N.?D7R2Y,?D+=K/W#24;B0SL&S
M5)%I9ZF0H!T6-JFD@4>P^P98B;=N/W)CKXYU3.U<QN-^@<QH7*YMUH,O?9T;
MJ&4:=-K1A3U6]3.GRU6LS.0A86SNFZIV3\A5%EVI6JR:?K\?BRJK1>]H[I:Y
M[CHIKC%`QD,C:^U(V7M=I2C`@-D<F]2-)`],7DL7(?&'D5P)!L?A?<UNV777
M:!:2.EB^V^_HH@_]>ECH8ZB!DDD@#J)(B0JR&5&;+5AR:9<>Q;^0WK0T:;G$
ML1X=4:9CGV@-Z8SD&F<5LB8_88QRQG;G\AJVHNVP"9DV=+?38B/V3)-$A`5)
M)35.\>7[A]K*WVNW(F!DT`B-?D.ISEE(^D$Y+]62CU2U[LOC=^W+M#]>H8#?
M>9Z^!TI#4LC5DQ/1W&E=%!0J>DCQKW)?[0:9Q[=545UE<0X/AK9^"\-GIXO$
MKI$,6MN582!VMWLUBC).*GXZ^SEJ13(ZD[@PLD&S?(JK$.U3.V30*@#0H-_'
MQ'LG;T6VWVM'#IMDJ@/D<G9@0PD9O4N&4,">@R`RT],9-5?E#S%7\TTO/-;<
M1+OBAF9J<.FJF@A=)(GI(H"=*4[PRR1,JD2$.TAD[Q[F'^\EN*]8/#!@\,&#
MPP8/#!@\,&#PP8/#!@\,&/0Z=-F+9P]>N$&C-H@LZ=NW2R;=LU;-TS*KN'"Z
MIB)((()$$QSF$"E*`B(@`>>&954LQ`4#,D^@&/9%%+/*L$"L\SL%55!+,Q.0
M``ZDD]`!U)Z#&,OD=L6R=]W-Y'A_QYLTI4N#6+3(3-_OD>FM^-LS*)?&8/M,
MF$A^-&7>3#HBC*E12_Z/0QGRI2>K@6];KS<;ERON?_';.[1[7IFU2./1@#D9
M#\R3TA4_[C^;3M;QKLS9?[?G!9YEY&I8JSGB]P]NDI7(UP-(NI:*,]3&L:Y2
M7*=>N8$"$Y1=W6EQ[X^9-Q;R.H8CBE49U"@4Q@5I'L&X`H]D7AP*:1L$_(B4
MKB:L<VZ`5WCQ;U465,/]B@4I7_:+1;[%;X[9;(Q'21#(#XD_%F/YF8]23ZG&
M0O(O(N[^5MX5F^M\5;UFX:V34[GHJ*/HBB3TCAB7VQQKT51\223VGSIXA&#P
MP8/#!@\,&#PP8/#!@\,&#PP8/#!@\,&%`Y\U&#O?#OD#5[9K=OPVE2>>RP7S
M3Z)3Y6^V>M41M\;JXF9U6!CY2<E&<A7D7#5Z5F@9P1BLL8@D$/>6.[LIXJK;
ME7!45$E+3-">Y*B&1EC'5\E4%B"N8;(9Z2<LO7#D\?;Q7V'F;;UUM%GH[]?(
MKC']I0U51'20S539K3:IY72)&28H\7<8(950,&STE!NBNB<)\XXQW6L<0-UC
M.1DDAH[UULFG_P#G]MS"P2,V[0,I3(U[3;U'L+%&P,35/8DR,`KL5W@/E$5/
MD,N0D3XLI=LT=DE@V[5+6.)B9I>V\3%C]`*2`,%"]!ZJ3K(.>8%@O/6_\X[E
MY1H;IS)89=MTK6Q5MU#]W3UT*1*<JEUJ:5WA>62?-I![)5C^W5UTB-FMQXSL
'49P>&#'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
